Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1906 • ACR Convergence 2023
Implementation Practices for the 2022 American College of Rheumatology Guidelines for Exercise, Rehabilitation, Diet, and Additional Integrative Interventions for Rheumatoid Arthritis
Laura Nichols¹, Meghan Scheibe², Ellen Erie³, Austin Nickell³ and Abe Sahmoun³, ¹Sanford Health, Fargo, ND, ²Sanford Health, West Fargo, ND, ³University of North Dakota, Fargo, ND
Background/Purpose: In November 2022, the American College of Rheumatology (ACR) released the ACR Guidelines for Exercise, Rehabilitation, Diet, and Additional Integrative Interventions for Rheumatoid Arthritis…
Abstract Number: 2098 • ACR Convergence 2023
Contribution of Rare Deleterious Exonic Variants in Telomere Related Genes to Interstitial Lung Disease Risk in Patients with Rheumatoid Arthritis
Pierre-Antoine Juge¹, Leticia Kawano-Dourado², Steven Gazal³, Gregory McDermott⁴, Keigo Hayashi⁴, Jing Cui⁵, Marie-Pierre Debray⁶, Lidwine Stervinou-Wemeau⁷, Syvain Marchand-Adam⁸, Christophe Richez⁹, Hilario Nunes¹⁰, Jérôme Avouac¹¹, Rene-Marc Flipo¹², Vincent Cottin¹³, Martin Soubrier¹⁴, Nathalie Saidenberg Kermanac'h¹⁰, Caroline Kannengiesser¹⁵, Raphael Borie¹⁶, Bruno Crestani¹⁷, Tracy J. Doyle⁴, Soumya Raychaudhuri⁴, Elizabeth Karlson⁴, Jeffrey Sparks¹⁸ and Philippe Dieudé¹⁹, ¹Division of Rheumatology, Inflammation, and Immunity Brigham & Women's Hospital, Boston, MA, ²Hospital do Coração (HCor), São Paulo, Brazil, ³University of South California, Los Angeles, CA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶CHU Bichat, Radiology, Paris, France, ⁷CHRU de Lille, Lille, France, ⁸CHU Tours, Tours, France, ⁹Université de Bordeaux, Bordeaux, France, ¹⁰CHU Avicenne, Bobigny, France, ¹¹Service de Rhumatologie, Hôpital Cochin, AP-HP.Centre – Université Paris Cité, Paris, France, ¹²La Lettre du Rhumatologue, Paris, France, ¹³Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France, ¹⁴Gabriel-Montpied Hospital, Clermont-ferrand, France, ¹⁵CHU Bichat, Paris, France, ¹⁶Bichat-Claude Bernard, Universite de Paris, Paris, France, ¹⁷Hopital Bichat, Paris University, Paris, France, ¹⁸Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ¹⁹Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, INSERM UMR1152, University de Paris Cité, Department of Rheumatology, Paris, France
Background/Purpose: RA-associated interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF) share genetic risk factors such as MUC5B rs35705950. The exact role of telomere related…
Abstract Number: 2116 • ACR Convergence 2023
Risk of Tuberculosis in Patients with Rheumatoid Arthritis: A Nationwide Population-based Cohort Study
Hyungjin Kim¹, Yeonghee Eun², Seonyoung Kang³, Jaejoon Lee³, Hoon-Suk Cha³, Jong Ho Cho⁴, Kwangmo Yang⁴, Kyungdo Han⁵ and Dong Wook Shin⁶, ¹Department of Medical Humanities, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ²Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, ³Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁴Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁵Department of Statistics and Actuarial Science, Soongsil University, Seoul, South Korea, ⁶Department of Family Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Background/Purpose: Patients with rheumatoid arthritis (RA) are known to have an increased risk of tuberculosis, particularly in association with the use of biologic disease-modifying anti-rheumatic…
Abstract Number: 2132 • ACR Convergence 2023
Systematic Screening for Multimorbidities Leads to an Increased Use of Comorbidity-preventing Medications and Lower Hospitalization Rates
Claire Daien¹, Vera Georgescu², Guillaume Decarriere³, Gael Mouterde³, Cedric Lukas⁴, Gregoire Mercier² and JACQUES MOREL⁵, ¹University Hospital, Montpellier, France, ²Department of Medical Information, Montpellier, France, ³Rheumatology, Montpellier, France, ⁴CHU Montpellier, Montpellier, France, ⁵Protocole thérapeutique immuno-rhumatologie, Montpellier, France
Background/Purpose: Systematic screening for multimorbidities has been carried out since 2014 at Montpellier University Hospital in patients with chronic inflammatory rheumatism (IRD). The aim of…
Abstract Number: 2148 • ACR Convergence 2023
Do High RF Titers Impact Response to TNF Inhibitors? Comparison of Certolizumab Pegol and Adalimumab in Patients with RA and High Titers of RF: A Post Hoc Analysis of a Phase 4 Trial
Josef S Smolen¹, Peter C. Taylor², Yoshiya Tanaka³, Carlos Cara⁴, Bernard Lauwerys⁵, Ricardo Xavier⁶, Jeffrey R Curtis⁷, Ted R Mikuls⁸ and Michael Weinblatt⁹, ¹Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, ²Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ³University of Occupational and Environmental Health, Kitakyushu, Japan, ⁴UCB Pharma, Madrid, Spain, ⁵UCB Pharma, Brussels, Belgium, ⁶Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ⁷Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, ⁸Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁹Division of Rheumatology, Inflammation and Immunity, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Background/Purpose: In patients with RA, high RF titers are considered a poor prognostic factor and are associated with higher disease activity, risk of radiographic progression,…
Abstract Number: 2165 • ACR Convergence 2023
Efficacy of Abatacept in Rheumatoid Arthritis- associated Usual Interstitial Pneumonia. National Multicenter Study of 233 Patients During a Long-Term Follow Up
Belén Atienza-Mateo¹, Ana Serrano-Combarro², Natividad del Val del Amo³, Ivette Casafont-Sole⁴, Rafael Benito Melero-Gonzalez⁵, Isabel Serrano-García⁶, Santos Castañeda⁷, Jerusalem Calvo⁸, Natalia Mena Vazquez⁹, Nuria Vegas Revenga¹⁰, Lucía Domínguez-Casas¹¹, Maria Camila Osorio Sanjuan¹², Carolina Díez Morrondo¹³, Lorena Perez-Albadalejo¹⁴, Ruben Lopez-Sanchez¹⁵, Maria Guadalupe Mazano Canabal¹⁶, Anahy Maria Brandy-Garcia¹⁷, Patricia Lopez-Viejo¹⁸, Gema Bonilla¹⁹, Olga Maiz-Alonso²⁰, Carmen carrasco-Cubero²¹, Marta Garijo Bufort²², Mireia Moreno²³, Ana Urruticoechea²⁴, Sergio Ordonez-Palau²⁵, Carmen Gonzalez-Montagut Gomez²⁶, andrea Garcia-Valle²⁷, Juan Ramon De Dios²⁸, Fernando Lozano²⁹, Tomás Vazquez-Rodriguez³⁰, Patricia Carreira²⁹, Juan Maria Blanco-Madrigal³¹, SARA MARIA ROJAS HERRERA³², Ignacio Brana Abascal³³, Jesus Loarce-Martos³⁴, Emilio Giner-Serret³⁵, Juan Camilo Sarmiento-Monroy³⁶, Clara ventin-Rodriguez³⁷, Marina Rodriguez-lopez³⁸, Pablo Andujar-Brazal³⁹, Julia Fernandez-Melon⁴⁰, Lilian Maria Lopez⁴¹, carlos Fernandez-Diaz⁴², Javier Loricera⁴³, Ivan Ferraz Amaro⁴⁴, Diego Ferrer⁴⁵, Ricardo Blanco⁴⁶ and On behalf of the Collaborative Group Members⁴⁷, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain, ³Complejo Hospitalario de Navarra, Pamplona, Spain, ⁴Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁵CHU Vigo, O Carballino, Spain, ⁶Division of Rheumatology, H. Puerta del Mar, Cádiz, Spain, ⁷Hospital Universitario de la Princesa, Madrid, Spain, ⁸Reina Sofia University Hospital, Córdoba, Spain, ⁹IBIMA, Málaga, Spain, ¹⁰Hospital Galdakao- Usansolo, Galdakao, Spain, ¹¹Division of Rheumatology, Hospital San Agustín, Avilés, Spain, ¹²Division of Rheumatology, H.U. Lozano Blesa, Zaragoza, Spain, ¹³Division of Rheumatology, Hospital de León, León, Spain, ¹⁴Division of Rheumatology, Hospital Universitario de Jaén, Jaén, Spain, ¹⁵Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain, ¹⁶Complejo Asistencial de Zamora, Zamora, Spain, ¹⁷Hospital Germans Trias i Pujol, Badalona, Spain, ¹⁸Division of Rheumatology, Hospital Severo Ochoa, Leganéz, Spain, ¹⁹Department of Rheumatology, Hospital Clínico Universitario La Paz, Madrid, Spain, ²⁰University Hospital Donostia, San Sebastian, Spain, ²¹Department of Rheumatology, Hospital Universitario de Badajoz, Badajoz, Spain, ²²H. de Sagunto, Valencia, Italy, ²³Parc Tauli Hospital Universitari, I3PT(UAB), Barcelona, Spain, ²⁴Hospital Can Misses, Ibiza, Spain, ²⁵H. Arnau de Vilanova, Lleida, Spain, ²⁶H. Clínico Universitario de Valladolid, Valladolid, Spain, ²⁷Division of Rheumatology, Complejo Asistencial Universitario de Palencia, Palencia, Spain, ²⁸Hospital Universitario Araba, Vitoria, Spain, ²⁹Hospital Universitario 12 de Octubre, Madrid, Spain, ³⁰Rheumatology, Complejo Hospitalario Universitario de Ferrol, A Coruña, Spain, ³¹Division of Rheumatology, H. Universitario de Basurto, Bilbao, Spain, ³²Division of Rheumatology, Hospital de Mérida, Mérida, Spain, ³³Division of Rheumatology, Hospital Universitario Central de Asturias, Oviedo, Spain, ³⁴Ramón y Cajal University Hospital, Madrid, Spain, ³⁵Hospital Royo Villanova, Teruel, Spain, ³⁶Hospital Clínic, Barcelona, Spain, ³⁷Division of Rheumatology, Hospital Universitario de A Coruña, A Coruña, Spain, ³⁸Division of Rheumatology, Hospital Clínico Universitario de Santiago, La Coruna, Spain, ³⁹Division of Rheumatology, Hospital Universitario Doctor Peset, Valencia, Spain, ⁴⁰Division of Rheumatology, Hospital Universitario Son Espases, Palma de Mallorca, Spain, ⁴¹Division of Rheumatology, Hospital Universitario Son Llàtzer, Mallorca, Spain, ⁴²Division of Rheumatology, Hospital Universitario Reina Sofía, Murcia, Spain, ⁴³Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴⁴Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁴⁵Division of Pneumology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴⁶Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴⁷Spanish Collaborative Group of Interstitial Lung Disease Associated with Rheumatoid Arthritis, Spain, Spain
Background/Purpose: Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Usual interstitial pneumonia (UIP) is the most frequent, and severe ILD…
Abstract Number: 2433 • ACR Convergence 2023
Longitudinal Multi-Omics Single Cell Analysis Reveals Abatacept Treatment Shifts Peripheral Lymphocyte Subpopulations in Seropositive RA with Reduction of Mature B Cells and Retention of Transitional and Naive B Cells
Gregg Silverman¹, William Rigby², Helena Jun¹, Jasmine Shwetar¹, Katie Tumang¹, Sergei Koralov³, Ellie Ivanova¹, David Mieles¹, Sladjana Skopelia-Gardner⁴ and Kelly Ruggles¹, ¹NYU Grossman School of Medicine, New York, NY, ²Hitchcock-Dartmouth Medicine Center, Hanover, NH, ³NYU Grossman Schoolof Medicine, New York, NY, ⁴Hitchcock-Dartmouth Medicine Center, Lebanon, NH
Background/Purpose: Biologic agents of diverse molecular mechanisms of action are approved for RA, but we do not have a full understanding of the implications of…
Abstract Number: 2503 • ACR Convergence 2023
Cytokines Regulate the Fibrotic Response of Growth Factors in Joint Fibroblast-like Synoviocytes
Sofie Falkenløve Madsen¹, Mikkel Rathsach Andersen², Alexander Scheller Madrid², Signe Holm Nielsen³, Morten Karsdal³, Christian Thudium³ and Anne-Christine Bay-Jensen³, ¹University of Copenhagen, Herlev, Denmark, ²Herlev-Gentofte Hospital, Gentofte, Denmark, ³Nordic Bioscience, Herlev, Denmark
Background/Purpose: Rheumatoid arthritis (RA) and osteoarthritis (OA) are characterized by inflammation, joint swelling, stiffness, and pain. A fibroid phenotype has been identified in RA, where…
Abstract Number: 2586 • ACR Convergence 2023
A Novel Blood-Based Assay Differentiates Seropositive and Seronegative Rheumatoid Arthritis from Healthy Individuals and Those with Other Inflammatory Diseases or Osteoarthritis
Peter C. Taylor¹, Jenya Antonova², Jennifer Geis³, Katharine Dilger³, David Chernoff⁴, Diana Abdueva³, Nancy Shadick⁵ and Michael Weinblatt⁶, ¹Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Compass Strategy and Research, Inc., San Francisco, CA, ³Aqtual Inc., Hayward, CA, ⁴Chernoff Consulting, Sausalito, CA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Harvard Medical School, Waban, MA
Background/Purpose: Non-invasive differentiation of seropositive and seronegative rheumatoid arthritis (RA) from other conditions has been limited in the current practice. We aimed to evaluate the…
Abstract Number: 0011 • ACR Convergence 2023
Clock Gene Bmal1 Promotes Transcriptional Activity of NF-κB to Regulate Production of Inflammatory Mediators in RA-FLS
Hikari Tsukamoto¹, Kenta Kaneshiro², Kohsuke Yoshida¹, Koji Tateishi³, Yasuhiro Terashima³, Nao Shibanuma⁴, Yoshitada Sakai⁵ and Akira Hashiramoto¹, ¹Kobe University Graduate School of Health Sciences, Kobe, Japan, ²Kobe University Graduate School of Health Sciences, Osaka, Japan, ³Kohnan Kakogawa Hospital, Kakogawa, Japan, ⁴Kobe Kaisei Hospital, Kobe, Japan, ⁵Kobe University Graduate School of Medicine, Kobe, Japan
Background/Purpose: Rheumatoid arthritis (RA), an autoimmune polyarthritis characterized by 'tumor-like' proliferation of RA fibroblast-like synovial cells (RA-FLS), has characteristic symptoms such as "morning stiffness of…
Abstract Number: 0073 • ACR Convergence 2023
PD-1hi Cells Are Highly Present in the Rheumatoid Joint, and Express Regulatory Capacities
Sofie Rask¹, Christian Andersen², Malene Hvid¹, Kim Ravnskjær², Bent Deleuran¹ and Stinne Greisen³, ¹Aarhus University, Aarhus, Denmark, ²University of Southern Denmark, Odense, Denmark, ³Aarhus University/Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Programmed death 1 (PD-1) is an immune checkpoint receptor expressed by activated T cells, and of major importance in maintaining peripheral tolerance. Expression of…
Abstract Number: 0174 • ACR Convergence 2023
Evaluation of Healthcare Utilization in Members with Rheumatoid Arthritis, Psoriatic Arthritis, and Systemic Lupus Erythematosus
Jean Park, W. Cliff Rutter, Elisea Avalos-Reyes, Chen Liu, Will Cavers, Dorothea Verbrugge and Kjel Johnson, CVS Health, Woonsocket, RI
Background/Purpose: Healthcare utilization is increasing among patients with rheumatic diseases. While several studies have assessed healthcare utilization in rheumatoid arthritis (RA) patients, few studies have…
Abstract Number: 0380 • ACR Convergence 2023
Use of Digital Health Tools to Evaluate Change in Clinical and Patient-Reported Outcomes Among Patients with Rheumatoid Arthritis Initiating Treatment with a JAKi or TNFi
W. Benjamin Nowell¹, Cassie Clinton², Fenglong Xie², Yuji Su³, Laura Stradford¹, David Curtis⁴, Patrick Zueger⁵, Pankaj Patel⁶, Kelly Gavigan⁷, Shilpa Venkatachalam⁸, Esteban Rivera⁹ and Jeffrey R. Curtis³, ¹Global Healthy Living Foundation, Nyack, NY, ²University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham and Illumination Health, Birmingham, AL, ⁴Global Healthy Living Foundation, San Francisco, CA, ⁵AbbVie, Inc., Mettawa, IL, ⁶AbbVie, Inc., North Chicago, IL, ⁷Global Healthy Living Foundation, Upper Nyack, NY, ⁸Global Healthy Living Foundation, New York, NY, ⁹Global Healthy Living Foundation, Long Island City, NY
Background/Purpose: Although the use of patient-reported outcome (PRO) data has grown more common in the care of people with rheumatoid arthritis (RA), the utility of…
Abstract Number: 0396 • ACR Convergence 2023
Hydroxychloroquine Is Associated with a Decreased Risk of Non-alcoholic Fatty Liver Disease in Patients with Rheumatoid Arthritis: A Population-based, Cohort Study
Hsin-Hua Chen¹ and DER-YUAN CHEN², ¹Taichung Veterans General Hospital, Taichung, Taiwan, ²Center of Rheumatology, China Medical University Hospital, Taichung, Taiwan
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune inflammatory disease characterized by chronic destructive arthritis and extra-articular involvement. Prior studies showed patients with RA had…
Abstract Number: 0413 • ACR Convergence 2023
Transcriptomic Analysis of Peripheral Blood Mononuclear Cells Reveals Pain and Inflammation Specific Alterations in Difficult-to-treat Rheumatoid Arthritis
Lilla Gunkl-Tóth¹, Gábor Sütő², Gábor Kumánovics³, József Kun⁴, Péter Urbán⁵, Attila Gyenesei⁵, Panna Királyhidi⁶, Georg Schett⁷, György Nagy⁸ and Zsuzsanna Helyes⁹, ¹Department of Pharmacology and Pharmacotherapy, University of Pécs, Hungary; Eötvös Loránd Research Network, University of Pécs, Chronic Pain Research Group, Budapest, Hungary, ²Second Department of Medicine and Nephrology-Diabetes Centre, University of Pécs, Pécs, Hungary, ³Department of Rheumatology and Immunology, Medical School, University of Pécs, Pécs, Hungary, ⁴Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, Pécs, Hungary; Bioinformatics Research Group, Genomics and Bioinformatics Core Facility, Szentágothai Research Centre, University of Pécs, Budapest, Hungary, ⁵Bioinformatics Research Group, Genomics and Bioinformatics Core Facility, Szentágothai Research Centre, University of Pécs, Pécs, Hungary, Pécs, Hungary, ⁶Department of Genetics, Cell- and Immunobiology, Semmelweis University School of Medicine, Budapest, Hungary, ⁷Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ⁸Department of Rheumatology and Clinical Immunology, Semmelweis University School of Medicine; Department of Genetics, Cell and Immunobiology, Semmelweis University, Budapest, Hungary; Heart and Vascular Centre, Semmelweis University, Budapest, Hungary, ⁹Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, Pécs, Hungary; Eötvös Loránd Research Network, University of Pécs, Chronic Pain Research Group, Pécs, Hungary; National Laboratory for Drug Research and Development, Pécs, Hungary
Background/Purpose: Despite novel treatment strategies in rheumatoid arthritis (RA), approximately 20-30% of patients remain symptomatic. The EULAR definition of difficult-to-treat (D2T) RA has recently been…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].